A device for supporting the breast milk microbiome.

微生物组描述了生活在我们身上和体内的微生物的集合，包括细菌。健康的微生物群对调节消化、免疫和代谢功能至关重要。母乳**占婴儿肠道中首批有益细菌的** 40%**，没有母乳的婴儿**容易**感染微生物组相关疾病，如坏死性小肠结肠炎（NEC）、糖尿病、肠易激综合征和肥胖症。然而，目前全球母乳喂养率很低，某些婴儿（如早产、剖腹产和配方奶喂养的婴儿）获得母乳的机会减少。因此，这些婴儿特别容易感染上述疾病。BoobyBiome热衷于通过利用微生物群的力量，为那些无法或难以母乳喂养的人设计产品，赋予父母**权力，改善婴儿**健康**。目前，BoobyBiome正在开发一种母乳来源的微生物组补充剂，用于微生物组受损的婴儿。在进行BoobyBiome的研究和开发过程中，我们意识到一些母乳喂养方法会降低母乳中阳性微生物群落的生存能力。考虑到这一点，我们努力实施**多方面的**方法，通过**恢复**这些婴儿所缺乏的细菌来改善婴儿肠道健康。在这个项目中，BoobyBiome打算开发一种优化母乳的方法，这样所有的婴儿都可以获得与健康微生物群相关的大量功能，而不管他们是如何获得母乳的。在这个项目中，BoobyBiome将1)开发一个**原型**，2)对原型**测试进行有效的迭代**，3)完成一个**专利、商标和最终产品。**作为BoobyBiome的首席执行官，**博士。** **Lydia Mapstone**，我相信我们作为一个由女性企业家**和科学家**组成的**团队有能力实现这些成果，同时我们也努力成为婴儿微生物组领域的**领导者**。完成这些里程碑的关键是我们**经验丰富的咨询团队**以及与学术界的密切联系，包括我们的科学合作者**博士。伦敦大学学院儿童健康研究所的Bajaj-Elliott**说。****有效**和**负担得起**获得母乳微生物群落可使所有婴儿形成健康的微生物群，而每位父母都应提供这种微生物群。最终，BoobyBiome的目标是通过这个项目提供一种所有婴儿都可以使用的产品，包括剖腹产婴儿、配方奶喂养的婴儿、早产儿和同性父母的婴儿。我们致力于生产一种**科学有效的产品**，这种产品**有可能在医疗保健领域产生真正的**变化**。这样做，我们将成为所有家长可靠和值得信赖的公司。

The **microbiome** describes the collection of microorganisms, including bacteria, which reside on and in us. A healthy microbiome is crucial in regulating digestive, immune and metabolic functions. Babies **without** access to breastmilk, which **contributes 40%** of the first beneficial bacteria in infants' guts, are **vulnerable** to microbiome-related diseases such as necrotising enterocolitis (NEC), diabetes, IBS and obesity. However, current global rates of **breastfeeding are poor**, with certain babies such as preterm, C-section and formula-fed infants having reduced access to breastmilk. Consequently, these babies are particularly vulnerable to the aforementioned diseases.BoobyBiome is passionate about **empowering parents** and improving the **health** of their babies through designing products for those **unable** or struggling to breastfeed, by harnessing the power of the microbiome. Currently, BoobyBiome is developing a **breastmilk-derived** microbiome supplement for infants with **compromised microbiomes**. In conducting research and development for BoobyBiome, we have realised that some methods of breastfeeding **diminish the viability** of positive microbial communities in breast milk. With this in mind, we endeavour to implement a **multi-faceted** approach to improving infant gut health by **recovering** the bacteria that these babies are lacking.With this project, BoobyBiome intends to develop a method for **optimising** breastmilk such that all babies may be able to receive the vast array of functions associated with a healthy microbiome, irrespective of how they receive their milk. In this project BoobyBiome will 1) develop a **prototype**, 2) conduct effective iterations of prototype **testing** and 3) finish with a **patented, trademarked and finalised product.**As CEO of BoobyBiome, **Dr.** **Lydia Mapstone**, I am confident in our ability as a **team of female entrepreneurs** and scientists to meet these deliverables, in tandem with our efforts to be **leaders** in the infant microbiome sector. Key to completion of these milestones is our **experienced advisory team** and close associations with the academic community, including our scientific collaborator **Dr. Bajaj-Elliott** of the **UCL Institute of Child Health.****Effective** and **affordable** access to breastmilk microbial communities allows for all babies to develop a healthy microbiome and every parent to provide that. Ultimately, BoobyBiome aims to deliver a product from this project that is accessible to all babies, including C-section, formula-fed babies, preterm babies and babies of same-sex parents. We are committed to producing a **scientifically-valid product** which has the potential to exert real **change** in the healthcare sector. In doing so, we will be a reliable and trusted company to all parents.